Program
Hydroxyurea
Also written as “Hydroxyurea (HU)”, “Hydroxycarbamide” and “Hydroxycarbamid”.
Its studies are mostly in HIV Infections · Anemia, Sickle Cell · Polycythemia Vera · Glioblastoma, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Norgine | 51 open or running | phase 4since Aug 4, 2015 | Aug 4, 2015 | Feb 2028phase 2 · NCT06578507 |
| Novartis | 20 open or running | phase 4since May 2, 2023 | Feb 10, 2006 | none ahead |
| Nova Laboratories | 10 open or running | phase 2since Dec 3, 2018 | Dec 3, 2018 | none ahead |
| Triangle Pharmaceuticals | 10 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
Also a collaborator on its studies: simbec-orion-group, oncodesign-sa, phinc-development, Pfizer and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: phase 2 study in HIV InfectionsNew to Triangle PharmaceuticalsTriangle Pharmaceuticals · NCT00002412 · United States
- Feb 10, 2006Novartis's first study: phase 2 study in GlioblastomaNew to NovartisNovartis · NCT00290771 · 231 enrolled · United States
- Aug 4, 2015Norgine's first study: phase 4 study in Anemia, Sickle CellNew to NorgineNorgine · NCT02522104 · 40 enrolled · France
- Dec 3, 2018Nova Laboratories's first study: phase 2 study in Anemia, Sickle CellNew to Nova LaboratoriesNova Laboratories · NCT03763656 · 33 enrolled · Jamaica, United Kingdom
- Jan 9, 2019Phase 2 study in Anemia, Sickle CellNorgine · NCT03806452 · 86 enrolled · Côte D'Ivoire, France, Guadeloupe and more
- Aug 5, 2021Phase 1 study in Healthy VolunteersNorgine · NCT05025072 · 28 enrolled · United Kingdom
- Jul 19, 2022Phase 2 study in Anemia, Sickle CellNorgine · NCT05470270 · 33 enrolled · France
- May 2, 2023Phase 4 study in Polycythemia VeraNovartis · NCT05853458 · 76 enrolled · Germany
- Aug 22, 2024Phase 2 study in Anemia, Sickle CellNorgine · NCT06578507 · 50 planned · France, French Guiana
- Oct 1, 2026Primary completion moved from 2027-02 to 2028-02Date moved laterphase 2 · +12 months · NCT06578507
Ahead
- Feb 2028Primary completion: phase 2 study in Anemia, Sickle CellNorgine · NCT06578507
TargetBeta
“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Gemcitabinerule | Eli Lilly | phase 4 | 224 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06578507Anemia, Sickle Cell · France, French Guiana | 2 | Recruiting | Norgine | Feb 2028 | 50 |
| NCT05853458Polycythemia Vera · Germany | 4 | Terminated | Novartis | Feb 26, 2026 | 76 |
| NCT05470270Anemia, Sickle Cell · France | 2 | Completed | Norgine | Oct 28, 2022 | 33 |
| NCT05025072Healthy Volunteers · United Kingdom | 1 | Completed | Norgine | Sep 29, 2021 | 28 |
| NCT03806452Anemia, Sickle Cell · Côte D'Ivoire, France, Guadeloupe and more | 2 | Completed | Norgine | May 30, 2024 | 86 |
| NCT03763656Anemia, Sickle Cell · Jamaica, United Kingdom | 2 | Completed | Nova Laboratories | May 19, 2021 | 33 |
| NCT02522104Anemia, Sickle Cell · France | 4 | Completed | Norgine | Nov 2016 | 40 |
| NCT00290771Glioblastoma · United States | 2 | Terminated | Novartis | Aug 2008 | 231 |
| NCT00002412HIV Infections · United States | 2 | Completed | Triangle Pharmaceuticals |
How it is read
Names in the registry
- “Hydroxyurea”, 7 entries
- “Hydroxyurea (HU)”, 6 entries
- “Hydroxycarbamide”, 2 entries
- “Hydroxycarbamid”, 1 entry
- “Hydroxycarbamide film-coated tablet”, 1 entry
Conditions, from the studies’ own filings
- HIV Infections, 6 studies
- Anemia, Sickle Cell, 5 studies
- Polycythemia Vera, 1 study
- Glioblastoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.